Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens (Q37718228)

22 August 2017

1 reference

title

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens (English)

1 reference

22 August 2017

main subject

gram-positive bacteria

0 references

2

Michael J Rybak

1 reference

22 August 2017

Molly E Steed

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

30

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

375-389

1 reference

Epidemiology of staphylococcal resistance

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Increase in pneumococcus macrolide resistance, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Stability and stabilization studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.375

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.4.375

1 reference

22 August 2017

1 reference